Colorectal Cancer

Screening has improved the prevention and early detection of colorectal cancer, but how can it reach more people?

March is Colorectal Cancer Awareness month and I'm happy to be part of the sea of blue that is preventing others from enduring a diagnosis of colon cancer.

Following cancer treatment, I wanted to regain some strength and stamina. Where would I start?

Genetic testing is a fascinating and provocative aspect of medicine today as it has implications for our some of our most pronounced human experiences: life, death, reproduction, parenthood, familial bonds, and one's mortality.

Howard S. Hochster, an oncologist at Yale Cancer Center who specializes in gastrointestinal cancers, explains when and why individuals should consider colorectal cancer screening.

A potential biomarker called NRP-1 may indicate longer progression-free survival with tivozanib over Avastin for patients with metastatic colorectal cancer.

I realized I couldn't be the only person so devastated by the effects and aftermath of cancer treatment. I decided to become a yoga teacher to help other patients and survivors.

Patients with newly diagnosed metastatic colorectal cancer who had higher levels of vitamin D in their blood lived a median eight months longer and experienced greater disease-free survival after their cancer treatment.

One of the greatest challenges facing potential Lynch syndrome carriers is not having advice on the implications of a pending test and a subsequent positive result.

This Valentine's Day is extra special as our hearts are brimmed with happiness and our lives are filled with love. I recognize the courage and beauty it takes to live with cancer together.

My goal is to educate doctors around the globe about helping to diagnose Lynch syndrome and to continue to help patients who need support.

Phase 2 Chinese study shows famitinib, a multi-targeted tyrosine kinase inhibitor, led to a small improvement in progression-free survival in patients with advanced, previously treated metastatic colorectal cancer.

Last week, I walked the massive halls of Moscone West in San Francisco and attended the Gastrointestinal Cancers Symposium, better known as ASCO GI. It is a meeting I always feel quite privileged to attend; it offers a glimpse into the work, passion, and expertise that goes into the many aspects of being able to live with metastatic colon cancer.

The Food and Drug Administration's calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.

Patients with metastatic colorectal cancer treated with Cyramza and standard FOLFIRI lived a median of 1.6 months longer than patients treated with FOLFIRI alone, according to results from the phase 3 RAISE trial.

Intensifying the chemotherapy component of a standard regimen containing Avastin reduced the risk of death and increased five-year overall survival in newly diagnosed metastatic colorectal cancer.

Patients with newly diagnosed metastatic colorectal cancer (mCRC) who had higher levels of vitamin D in their blood lived a median of eight months longer and experienced greater disease-free survival after their cancer treatment, according to research reported at the 2015 Gastrointestinal Cancers Symposium.

As I count my many blessings, my wish for you is that you are able to hold fast to the moment and breathe in all that you have, all that is dear to you now and that you, too, will fill your stockings with the presence and love of the moment. Wishing you all a very Merry Christmas!

The annual meeting of the European Society for Medical Oncology (ESMO) was held in September to discuss the latest data on critical issues in cancer treatment, diagnostics, prevention, supportive care and more.

As new therapies enter the treatment landscape for metastatic colorectal cancer, oncology nurses become even more critical in educating patients about side effects and the importance of reporting adverse events promptly.

The NCNN recommends testing for Lynch syndrome for at-risk individuals, regardless of whether they have colorectal cancer.

When deciding on a cancer treatment—and determining its effectiveness—look for a biomarker.

Recent studies show that two common colorectal cancer screening practices are both effective.

The genetic disease, Lynch syndrome, can significantly increase the risk of colon and other cancers.

In the right cancer, radiation and chemotherapy can make a powerful duo.